DDrare: Database of Drug Development for Rare Diseases

Bupropion (DrugBank: Bupropion)

5 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	1
18	Spinocerebellar degeneration	1
21	Mitochondrial disease	1
96	Crohn disease	1
171	Wilson disease	1

8. Huntington disease [ 197 clinical trials, 171 drugs, (DrugBank: 54 drugs), 82 drug target genes, 144 drug target pathways]

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 197 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01914965 (ClinicalTrials.gov)	June 2012	31/7/2013	Apathy Cure Through Bupropion in Huntington's Disease	A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease	Apathy;Huntington's Disease	Drug: Bupropion;Drug: Placebo	Charite University, Berlin, Germany	University of Ulm;Ruhr University of Bochum;University Hospital Muenster	Completed	25 Years	75 Years	Both	40	Phase 2	Germany

18. Spinocerebellar degeneration [ 59 clinical trials, 78 drugs, (DrugBank: 28 drugs), 44 drug target genes, 59 drug target pathways]

Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 59 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01716221 (ClinicalTrials.gov)	October 2012	25/10/2012	An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	Friedreich Ataxia	Drug: bupropion & Citalopram;Drug: Bupropion & Placebo;Drug: Placebo & Citalopram;Drug: Placebo & Placebo	University of Colorado, Denver	NULL	Completed	N/A	N/A	Female	1	Phase 4	NULL

21. Mitochondrial disease [ 23 clinical trials, 29 drugs, (DrugBank: 28 drugs), 44 drug target genes, 65 drug target pathways]

Searched query = "Mitochondrial disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 23 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643249 (ClinicalTrials.gov)	November 10, 2020	13/11/2020	Drug-drug Interaction Study of KL1333 in Healthy Subjects	A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects	Mitochondrial Disease	Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide	Abliva AB	NULL	Recruiting	18 Years	65 Years	All	14	Phase 1	United Kingdom

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00126373 (ClinicalTrials.gov)	May 2005	2/8/2005	A Trial of Wellbutrin for Crohn's Disease	A Randomized Controlled Trial of Wellbutrin for Crohn's Disease	Crohn Disease	Drug: Wellbutrin (bupropion)	Altschuler, Eric, M.D.	GlaxoSmithKline	Completed	18 Years	N/A	Both	1	Phase 2;Phase 3	United States

171. Wilson disease [ 50 clinical trials, 59 drugs, (DrugBank: 17 drugs), 3 drug target genes, 28 drug target pathways]

Searched query = "Wilson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 50 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04526210 (ClinicalTrials.gov)	August 2020	19/8/2020	Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	Wilson Disease	Drug: ALXN1840;Drug: Bupropion Hydrochloride	Alexion Pharmaceuticals	NULL	Enrolling by invitation	18 Years	50 Years	All	38	Phase 1	United States